Press release
Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster
CELEBRATION, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) ("Zevra" or “the Company"), a rare disease company melding science,
About this update from Zevra Therapeutics, Inc.
[{"type":"text","content":"CELEBRATION, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (\"Zevra\" or “the Company\"), a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options, proudly welcomes Tom Anderson, a highly accomplished biopharma veteran, to its Board of Directors (the \"Board\"). Concurrently, the Company announces the retirement of board member Matthew R. Plooster, whose valuable leadership has played a crucial role in shaping Zevra's growth. Both the announcement of the new director and Mr. Plooster's retirement are in accordance with the plan announced by the Company on May 8, 2023. With over 35 years of experience as a leader in the biopharma and consumer product goods (CPG) industries, Tom Anderson brings significant expertise in high-growth organizations, operational and strategic roles in rare diseases, strategic acquisitions, and scaling businesses. As the CEO and Director of SwanBio Therapeutics and, formerly, a key member of Sage Therapeutics' leadership team, Tom has a proven track record of managing aggressive growth and driving shareholder value. \"Tom's appointment to the Zevra Board comes at a pivotal time for our company. His exceptional skill set and strategic insights will be instrumental as we continue to develop and bring much-needed therapies to the rare disease community,\" stated Tamara A. (Seymour) Favorito, Board Chair. \"Tom's wealth of experience in managing complex drug development challenges including strategic roles in rare disease and talent development aligns perfectly with our vision.\" \"I am delighted to join the Zevra Board at such a pivotal time in the Company's development. Collaborating with Zevra's Board and management team, I look forward to leveraging my operational and rare disease experience to help guide Zevra towards its mission, ensuring our collective efforts to expedite development and accessibility of life changing therapies directly benefit the rare disease community,\" Anderson added. Simultaneously, Zevra extends its sincere gratitude and best wishes to Matthew R. Plooster for his countless contributions and dedication during his tenure on the Board. Mr. Plooster, who has been a director of Zevra since March 2011 and Chairman of the Board from January 2023 to May 2023, play...